182 related articles for article (PubMed ID: 37577836)
1. Longitudinal surveillance of three biomarkers to predict recurrence of hepatocellular carcinoma after radical resection.
Tong JS; Lu CD; Lu CJ; Zheng S; Mao SQ
Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1178-1185. PubMed ID: 37577836
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
3. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study.
Wang MD; Sun LY; Qian GJ; Li C; Gu LH; Yao LQ; Diao YK; Pawlik TM; Lau WY; Huang DS; Shen F; Yang T
Int J Surg; 2022 Sep; 105():106843. PubMed ID: 35995351
[TBL] [Abstract][Full Text] [Related]
4.
Lee HA; Lee YR; Lee YS; Jung YK; Kim JH; An H; Yim HJ; Jeen YT; Yeon JE; Byun KS; Seo YS
World J Gastroenterol; 2021 Jul; 27(28):4687-4696. PubMed ID: 34366629
[TBL] [Abstract][Full Text] [Related]
5. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis.
Guan MC; Ouyang W; Liu SY; Sun LY; Chen WY; Tong XM; Zhu H; Yang T
Hepatobiliary Pancreat Dis Int; 2022 Dec; 21(6):559-568. PubMed ID: 35643910
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
Park SJ; Jang JY; Jeong SW; Cho YK; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Park S; Bang HI
Medicine (Baltimore); 2017 Mar; 96(11):e5811. PubMed ID: 28296720
[TBL] [Abstract][Full Text] [Related]
7. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
8. Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients.
Hadi H; Wan Shuaib WMA; Raja Ali RA; Othman H
Medicina (Kaunas); 2022 Jul; 58(8):. PubMed ID: 36013482
[TBL] [Abstract][Full Text] [Related]
9. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma.
Miyaaki H; Nakashima O; Kurogi M; Eguchi K; Kojiro M
J Gastroenterol; 2007 Dec; 42(12):962-8. PubMed ID: 18085353
[TBL] [Abstract][Full Text] [Related]
10. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
[TBL] [Abstract][Full Text] [Related]
11. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.
Xu F; Zhang L; He W; Song D; Ji X; Shao J
Dis Markers; 2021; 2021():8868370. PubMed ID: 33628341
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma.
Wang G; Lu X; Du Q; Zhang G; Wang D; Wang Q; Guo X
Sci Rep; 2020 Aug; 10(1):13519. PubMed ID: 32782270
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma.
Wang Q; Chen Q; Zhang X; Lu XL; Du Q; Zhu T; Zhang GY; Wang DS; Fan QM
World J Gastroenterol; 2019 Sep; 25(36):5515-5529. PubMed ID: 31576097
[TBL] [Abstract][Full Text] [Related]
14. Effect of PIVKA-II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery.
Cai Y; Xie K; Adeeb Alhmoud MN; Lan T; Wan H; Hu D; Lan L; Liu C; Wu H
Cancer Med; 2023 Sep; 12(17):17866-17877. PubMed ID: 37596739
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of PIVKA-II in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study.
Zhu W; Wang W; Zheng W; Chen X; Wang X; Xie J; Jiang S; Chen H; Zhu S; Xue P; Jiang X; Li H; Wang G
Sci Rep; 2024 Apr; 14(1):8416. PubMed ID: 38600210
[TBL] [Abstract][Full Text] [Related]
16. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
[TBL] [Abstract][Full Text] [Related]
17. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.
Nanashima A; Taura N; Abo T; Ichikawa T; Sakamoto I; Nagayasu T; Nakao K
Dig Dis Sci; 2011 Oct; 56(10):3086-100. PubMed ID: 21706206
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma.
Tran VT; Phan TT; Nguyen TB; Le TT; Tran TT; Nguyen AT; Nguyen HT; Nguyen NB; Ho TT; Pho SP; Nguyen TT; Nguyen HT; Mai HT; Pham BT; Nguyen KD; Le BT; Nguyen TT; Nguyen ST
BMC Res Notes; 2023 Nov; 16(1):317. PubMed ID: 37932802
[TBL] [Abstract][Full Text] [Related]
19. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.
Kim DY; Toan BN; Tan CK; Hasan I; Setiawan L; Yu ML; Izumi N; Huyen NN; Chow PK; Mohamed R; Chan SL; Tanwandee T; Lee TY; Hai TTN; Yang T; Lee WC; Chan HLY
Clin Mol Hepatol; 2023 Apr; 29(2):277-292. PubMed ID: 36710606
[TBL] [Abstract][Full Text] [Related]
20. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
